Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Clover Biopharmaceuticals and Dynavax Technologies Corporation (NASDAQ:DVAX) have executed the commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant for use in Clover's protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).
- The commercial supply agreement extends to the end of 2022. It includes doses for delivery in 2021, manufactured under the previously announced funding agreement between Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax.
- Clover separately announced today an advanced purchase agreement with the Vaccine Alliance, GAVI, for supplying up to 414 million doses of SCB-2019 (CpG 1018/Alum) through 2022 to the COVAX Facility.
- Clover expects to commence the launch of SCB-2019 (CpG 1018/Alum) by the end of 2021.
- Price Action: DVAX shares are up 0.30% at $9.90 during the market session on the last check Wednesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!